Dexmedetomidine and Renal Transplants

N/ACompletedNCT02019121

University of California, Davis797 enrolled

Overview

Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function. Investigators hope to elucidate any association between renal transplant patients and perioperative dexmedetomidine administration, these include (but are not limited to) UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate. Investigators will research both living and cadaveric renal transplants.

Study Type

OBSERVATIONAL

Enrollment

797

Conditions

Renal Failure

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients greater than or equal to 18 years old that underwent renal transplant at UC Davis Medical Center - Exclusion Criteria: Patients that did not undergo renal transplants and patients less than 18 years old will be excluded from the study. \-

Locations (1)

UC Davis Health System

Sacramento, California, United States

Outcomes

Primary Outcomes

Cr/GFR improvement, postoperative mortality/morbidity (within 30 days) and overall complications

Time frame: 5 years

Secondary Outcomes

Graft failure, length of hospital stay (LOS), length of ICU stay, re-admission rate, infections, pulmonary complications.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.